About 3—5% of all patients with multiple sclerosis experience the onset of their disease under the age of 16. A significant proportion of paediatric multiple sclerosis patients develop significant cognitive disturbances and persistent physical disability. The high relapse rate and the morbidity in the paediatric multiple sclerosis population has triggered the use of disease-modifying therapies that have been shown to reduce relapse rate, disease progression and cognitive decline in adult patients with multiple sclerosis. Hard evidence for the right treatment and its appropriate timing is scarce in paediatric multiple sclerosis. Nevertheless, expertise in this field has grown thanks to recent open-label trials and experience generated in specialized centres. In spring 2009, a first meeting was held in Rotterdam with clinicians from 11 European countries (one from Canada) that are all active in the management of paediatric multiple sclerosis. One of the aims was to generate a common view on the management of paediatric multiple sclerosis patients. The result of this meeting is presented here to help standardize treatment and to support clinicians with less experience in this field.
Banwell B., Ghezzi A. and Bar-Orr A.Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol2007; 6: 887-902.
2.
Ghezzi A., Pozzilli C., Liguori M., et al. Prospective study of multiple sclerosis with early onset. Mult Scler2002; 8: 115-118.
3.
Renoux C., Vukusic S., Mikaeloff Y., et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med2007; 365: 2603-2613.
4.
Gusev E., Boiko A., Bikova O., et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg2002; 104: 203-207.
5.
Gorman MP, Healy BC, Polgar-Turcsanyi M. and Chitnis T.Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol2009; 66: 54-59.
6.
Boiko A., Vorobeychik G., Paty D., et al. Early onset multiple sclerosis: a longitudinal study. Neurology2002; 59: 1006-1010.
7.
Banwell BL and Anderson PEThe cognitive burden of multiple sclerosis in children. Neurology2005; 64: 891-894.
8.
MacAllister WS, Belman AL, Milazzo M., et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology2005; 64: 1422-1425.
9.
Amato M., Goretti B., Ghezzi A., et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology2008; 70: 1891-1897.
10.
Fisher JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon-beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol2000; 48: 885-892.
11.
Kappos L., Freedman M., Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol2009; 11: 987-997.
12.
Goodin DS, Frohman EM, Garmany GP, et al. Disease-modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology2002; 58: 169-178.
13.
Banwell B.Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother2005; 5: 391-401.
Pohl D., Waubant E., Banwell B., et al. Treatment of pediatric multiple sclerosis and variants. Neurology2007; 68(Suppl 2): S54-S65.
16.
Elovaara I. , Apostolski S., van Doorn P., et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological disorders. Eur J Neurol2008; 15: 893-908.
17.
Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol1999; 46: 878-886.
18.
Takahashi I., Sawaishi Y., Takeda O., et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol1997; 17: 83-87.
19.
The IFNB Multiple Sclerosis Study Group.Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology1993; 43: 655-661.
20.
The IFNB Multiple Sclerosis Study Group and the UBC MS/MRI Analysis Group.Interferon beta-1b in the treatment of MS: final outcome of the randomised controlled trial. Neurology1995; 53: 1277-1285.
21.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta 1-a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol1996; 39: 285-294.
22.
PRISM Study Group.Randomized double-blind placebo-controlled study of interferon beta 1-a in relapsing-remitting multiple sclerosis. Lancet1998; 352: 1498-1504.
23.
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology1995; 45: 1268-1276.
24.
Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med2000; 343: 898-904.
25.
Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001; 357: 1576-1582.
26.
Kappos L., Polman C., Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006; 67: 1242-1249.
27.
Comi G., Martinelli V., Rodegher M., et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet2009; 374: 1503-1511.
28.
Kappos L., Freedman MS, Polman C., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis. Lancet Neurol2007; 370: 389-397.
29.
Filippi M., Rovaris M., Inglese M., et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet2004; 364: 1489-1496.
30.
Soriani MP, Bonzano L., Roccatagliata L., et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis. A meta-analytic approach. Ann Neurol2009; 65: 268-275.
31.
Waubant E., Hietpas J., Stewart T., et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics2001; 32: 211-213.
32.
Mikaeloff Y. , Moreau T., Debouverie M., et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr2001; 139: 443-446.
33.
Kornek B., Bernert G., Balassy C., et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics2003; 34: 120-126.
34.
Pohl D., Rostasy K., Gartner J. and Hanefeld F.Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a . Neurology2005; 65: 888-890.
35.
Ghezzi A., Amato MP, Gallo P., et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (immunomodulatory treatment of early-onset MS) study group. Mult Scler2005; 11: 420-424.
36.
Pakdaman H. , Fallah A., Sahraian MA, et al. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics2006; 37: 257-260.
37.
Banwell B., Reder AT, Krupp L., et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology2006; 66: 472-476.
38.
Tenembaum SN and Segura MJInterferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology2006; 67: 511-513.
39.
Mikaeloff Y. , Caridde G., Tardieu M., et al. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative study . Eur J Paediatr Neurol2008; 12: 205-209.
40.
Ghezzi A., Amato MP, Annovazzi P., et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci2009; 30: 193-199.
41.
Trojano M., Pellegrini F., Paolicelli D., et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol2009; 66: 513-520.
42.
Rio J., Nos C., Tintorè M., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol2006 ; 59: 344-352.
43.
Portaccio E. , Zipoli V., Siracusa G., et al. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler2006; 12: 281-286.
44.
Freedman MS , Patry DG, Grand’Maison F., et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci2004 ; 31: 157-168.
45.
Rio J., Rovira A., Tintoré M., et al. Relationship between MRI lesion activity and response to IFNβ in relapsing- remitting multiple sclerosis patients. Mult Scler2008; 14: 479-484.
46.
Rio J., Castello J., Tintoré M., et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler2009; 15: 848-853.
47.
Rudick R., Lee J., Simon J., et al. Defining interferon β response status in multiple sclerosis . Ann Neurol2004; 56: 548-555.
48.
Tomassini V. , Paolillo A., Russo P., et al. Predictors of long-term clinical response to interferon β therapy in relapsing multiple sclerosis. J Neurol2006; 253: 287-293.
49.
Malucchi S. , Gilli F., Caldano M., et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology2008; 70: 1119-1127.
50.
Farrell R., Karoo R. and Leary S.Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler2008; 14: 212-218.
51.
Sørensen PS, Deisenhammer F., Duda P., et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol2005; 12: 817-827.
52.
Sørensen PS, Tscherning T., Mathiesen HK, et al. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology2006; 67: 1681-1683.
53.
Kappos L., Clanet M., Sandberg-Wollheim M., et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology2005; 65: 40-47.
54.
Capobianco M. , Rizzo A., Malucchi S., et al. Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Neurol Sci2008; 29: S227-S229.
55.
Polman CH, O’Connor PW, Havrdova E., et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899-910.
56.
Havrdova E. , Galetta S., Hutchinson M., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing- Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol2009; 8: 254-260.
57.
Yousry TA, Major EO, Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for Progressive Multifocal Leukoencephalopathy. N Engl J Med2006; 354: 924-933.
58.
Kappos L., Bates D., Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol2007; 6: 431-434.
59.
Boriello G. , Prosperino L., Lucchetti A. and Pozzilli C.Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol2009; 13: 67-71.
60.
Huppke P., Stark W., Zurcher C., et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol2008; 65: 1655-1658.
61.
Ghezzi A., Pozzilli C., Brescia-Morra V., et al. Safety and effectiveness of natalizumab in paediatric multiple sclerosis: results of 17 patients. Mult Scler2009; 15(Supp19): Abstracts MS Variants S151-S269, Poster 774.
62.
Ellis R. and Boggild M.Therapy related acute leukaemia with mitoxantrone: what is the risk and can we minimise it?Mult Scler2009; 15: 505-508.
63.
Martinelli V., Capra R., Cocco E., et al. High incidence of acute leukemia in multiple sclerosis patients treated with mitoxantrone: a retrospective multicentre Italian study. 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). Sept 11, 2009. Poster 824.
64.
Tullus K. and Marks SDVasculitis in children and adolescents: clinical presentation, etiopathogenesis, and treatment. Paediatr Drugs2009; 11: 375-380.
65.
Makhani N., Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology2009; 72: 2076-2082.
66.
Polman CH, Reingold SC, Barkhof F., et al. Ethics of placebo-controlled trials in multiple sclerosis: a reassessment. Neurology2008; 70: 1134-1140.
67.
Chabas D., Castello-Trivino T., Mowry EM, et al. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype. Neurology2008; 71: 1090-1109.
68.
Waubant E., Chabas D., Okuda DT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol2009; 66: 967-971.
